Evidence map›Paper›PMID 27258647›Full record

ArticlePloS one2016

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.

Francesca Lombardi, Simone Belmonti, Massimiliano Fabbiani, Matteo Morandi, Barbara Rossetti, Giacinta Tordini, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto, Francesca Montagnani

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02123433 (Serological Response to Antipneumococcal Vaccination and Consequent Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Positive Adults), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02123433 phase3completednot on this map

Serological Response to Antipneumococcal Vaccination and Consequent Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Positive Adults: a Prospective Study Using 13-valent Conjugate Vaccine

TypeinterventionalSponsorUniversity of SienaRan2011 to 2013Enrolled50ConditionsHIV Infection, Pneumococcal InfectionsArmspneumococcal conjugate 13 valent vaccine
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Francesca LombardiInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, Rome, Italy.
Simone BelmontiInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, Rome, Italy.
Massimiliano FabbianiInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, Rome, Italy.
Matteo MorandiDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, Siena, Italy.
Barbara RossettiUniversity Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Viale Bracci 16, Siena, Italy.
Giacinta TordiniDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, Siena, Italy.
Roberto CaudaInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, Rome, Italy.
Andrea De LucaDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, Siena, Italy.
Simona Di GiambenedettoInstitute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, Rome, Italy.
Francesca MontagnaniDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, Siena, Italy.
Università Cattolica del Sacro Cuore · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDefinition of the optimal pneumococcal vaccine strategy in HIV-infected adults is still under evaluation. We aimed to compare immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) versus the 23-valent polysaccharide vaccine (PPSV23) in HIV-infected adults.

methodsWe performed a pilot, prospective controlled study enrolling HIV-infected pneumococcal vaccine-naïve outpatients, aged 18-65 years with CD4 counts ≥200 cells/μL. Eligible subjects were recruited into two parallel groups: group 1 (n = 50) received two doses of PCV13 eight weeks apart, and group 2 (n = 50) received one dose of PPSV23, as part of their standard of care. Anti-pneumococcal capsular polysaccharide immunoglobulin G concentrations were quantified by ELISA at baseline, 8, 24 and 48 weeks. Clinical and viro-immunological follow-up was performed at the same time points. Unvaccinated, age-matched HIV-negative adults (n = 100) were also enrolled as baseline controls.

resultsPre-vaccination specific IgG titers for each pneumococcal antigen did not differ between study groups but they were constantly lower than those from the HIV-negative controls. After immunization, significant increases in IgG titers were observed in both study groups at each time point compared to baseline, but response to serotype 3 was blunted in group 1. Antibody titers for each antigen did not differ between study groups at week 48. Overall, the proportion of subjects achieving seroprotection and seroconversion to all serotypes was comparable between groups. A marked decrease in IgG levels over time was observed with both vaccines. No relevant adverse reactions were reported in either group.

conclusionsIn this population with favorable immune profile, no relevant differences were observed in immunogenicity between PCV13 and PPSV23. Both vaccines were safe and well tolerated.

trial registrationClinicalTrials.gov NCT02123433.

Indexed as

AdolescentAdultAgedAntigens, BacterialConfidence IntervalsFemaleHIV InfectionsHumansImmunoglobulin GMaleMiddle AgedPneumococcal VaccinesProspective StudiesSerogroupVaccines, ConjugateYoung Adult23-valent pneumococcal capsular polysaccharide vaccineAntigens, BacterialImmunoglobulin GPneumococcal VaccinesVaccines, Conjugate

Identifiers

PMID27258647
PMCPMC4892598
OpenAlexW2412443584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.